Leijen, S., Soetekouw, P., Jeffry Evans, T., Nicolson, M., Schellens, J., Learoyd, M., . . . Middleton, M. (2011). A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Chicago Style (17. basım) AtıfLeijen, S., et al. A Phase I, Open-label, Randomized Crossover Study to Assess the Effect of Dosing of the MEK 1/2 Inhibitor Selumetinib (AZD6244; ARRY-142866) in the Presence and Absence of Food in Patients with Advanced Solid Tumors. 2011.
MLA (9th ed.) AtıfLeijen, S., et al. A Phase I, Open-label, Randomized Crossover Study to Assess the Effect of Dosing of the MEK 1/2 Inhibitor Selumetinib (AZD6244; ARRY-142866) in the Presence and Absence of Food in Patients with Advanced Solid Tumors. 2011.